Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm

American Journal of Cancer Research

Volumn 6, Issue 1, 2016, Pages 27-37

  Wang, Chao ^a,b   Zhu, Xiaoyong ^a   Feng, Weiwei ^a   Yu, Yinhua ^a   Jeong, Kangjin ^b   Guo, Wei ^b   Lu, Yiling ^b   Mills, Gordon B ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

14 3 3 ; Endometrial cancer; Verteporfin; YAP

Indexed keywords

PROTEIN P53; PROTOPORPHYRIN; STRATIFIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VERTEPORFIN; YES ASSOCIATED PROTEIN;

ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; DRUG MECHANISM; DRUG SPECIFICITY; GENE SILENCING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION;

EID: 84976232067     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC and Guan KL. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761.
2. Oh H and Irvine KD. Yorkie: the final destination of Hippo signaling. Trends Cell Biol 2010; 20: 410-417.
3. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19: 491-505.
4. Zhao B, Li L, Lei Q and Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010; 24: 862-874.
5. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J and Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-905.
6. Henney JE. From the Food and Drug Administration. JAMA 2000; 283: 2779.
7. Pogue BW, O'Hara JA, Demidenko E, Wilmot CM, Goodwin IA, Chen B, Swartz HM and Hasan T. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Res 2003; 63: 1025-1033.
8. Schmidt-Erfurth U and Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45: 195-214.
9. Donohue E, Tovey A, Vogl AW, Arns S, Sternberg E, Young RN and Roberge M. Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J Biol Chem 2011; 286: 7290-7300.
10. Donohue E, Thomas A, Maurer N, Manisali I, Zeisser-Labouebe M, Zisman N, Anderson HJ, Ng SS, Webb M, Bally M and Roberge M. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. J Cancer 2013; 4: 585-596.
11. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D. Genetic and pharmacological disruption of the TEADYAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26: 1300-1305.
12. Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller JW, Gragoudas E and Vavvas DG. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res 2014; 124: 67-73.
13. Papazisis KT, Geromichalos GD, Dimitriadis KA and Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 1997; 208: 151-158.
14. Vichai V and Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006; 1: 1112-1116.
15. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A and Boyd MR. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990; 82: 1113-1118.
16. Mancini M, Corradi V, Petta S, Barbieri E, Manetti F, Botta M and Santucci MA. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther 2011; 336: 596-604.
17. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P, Danovi SA, Pardo O, Crook T, Mein CA, Lemoine NR, Jones LJ and Basu S. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008; 15: 1752-1759.
18. Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, Fassina A, Cordenonsi M and Piccolo S. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 2014; 158: 157-170.
19. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M and Piccolo S. Role of TAZ as mediator of Wnt signaling. Cell 2012; 151: 1443-1456.
20. Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, Shao DD, Schumacher SE, Weir BA, Vazquez F, Cowley GS, Root DE, Mesirov JP, Beroukhim R, Kuo CJ, Goessling W and Hahn WC. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012; 151: 1457-1473.
21. Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, Kuo CJ and Camargo FD. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013; 493: 106-110.
22. Levy D, Adamovich Y, Reuven N and Shaul Y. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 2007; 14: 743-751.
23. Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S and Columbano A. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol 2014; 61: 1088-1096.
24. Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G and Pili R. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene 2015; [Epub ahead of print].
25. Pozuelo-Rubio M. Regulation of autophagic activity by 14-3-3zeta proteins associated with class III phosphatidylinositol-3-kinase. Cell Death Differ 2011; 18: 479-492.
26. Rosenquist M. 14-3-3 proteins in apoptosis. Braz J Med Biol Res 2003; 36: 403-408.
27. Gardino AK and Yaffe MB. 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol 2011; 22: 688-695.
28. Aristizabal-Corrales D, Fontrodona L, Porta-dela-Riva M, Guerra-Moreno A, Ceron J and Schwartz S Jr. The 14-3-3 gene par-5 is required for germline development and DNA damage response in Caenorhabditis elegans. J Cell Sci 2012; 125: 1716-1726.
29. Angrand PO, Segura I, Volkel P, Ghidelli S, Terry R, Brajenovic M, Vintersten K, Klein R, Superti-Furga G, Drewes G, Kuster B, Bouwmeester T and Acker-Palmer A. Transgenic mouse proteomics identifies new 14-3-3-associated proteins involved in cytoskeletal rearrangements and cell signaling. Mol Cell Proteomics 2006; 5: 2211-2227.
30. Carrasco JL, Castello MJ and Vera P. 14-3-3 mediates transcriptional regulation by modulating nucleocytoplasmic shuttling of tobacco DNA-binding protein phosphatase-1. J Biol Chem 2006; 281: 22875-22881.
31. Mancini M, Veljkovic N, Corradi V, Zuffa E, Corrado P, Pagnotta E, Martinelli G, Barbieri E and Santucci MA. 14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia. Traffic 2009; 10: 637-647.
32. Dong S, Kang S, Lonial S, Khoury HJ, Viallet J and Chen J. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia 2008; 22: 572-577.
33. Ellis JJ, Valencia TG, Zeng H, Roberts LD, Deaton RA and Grant SR. CaM kinase IIdeltaC phosphorylation of 14-3-3beta in vascular smooth muscle cells: activation of class II HDAC repression. Mol Cell Biochem 2003; 242: 153-161.
34. Grozinger CM and Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci U S A 2000; 97: 7835-7840.
35. Zha J, Harada H, Yang E, Jockel J and Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 619-628.
36. Nomura M, Shimizu S, Sugiyama T, Narita M, Ito T, Matsuda H and Tsujimoto Y. 14-3-3 Interacts directly with and negatively regulates proapoptotic Bax. J Biol Chem 2003; 278: 2058-2065.
37. Zhang L, Chen J and Fu H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc Natl Acad Sci U S A 1999; 96: 8511-8515.
38. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868.
39. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC and Yaffe MB. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000; 19: 6778-6791.
40. Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, Gamblin SJ, Smerdon SJ and Cantley LC. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 1997; 91: 961-971.
41. Basu S, Totty NF, Irwin MS, Sudol M and Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11: 11-23.
42. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW and Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.